Bristol Myers lands $1.1B biobucks oncology pact with Volastra, a biotech with phones 'ringing off the hook'

Volastra announced Monday it was saddling up with the Big Pharma to develop up to three targets utilizing Volastra’s platform that targets chromosomal instability, a potentially valuable indicator the company says is present in up to 80% of cancers. BMS will pay $30 million in upfront cash, but Volastra stands to gain as much as $1.1 billion in milestone payments should the targets pan out.